HEMOSTATIC COMPOSITIONS
The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.
1 . A hemostatic composition comprising:
a) a biocompatible polymer in particulate form suitable for use in hemostasis; and
b) one hydrophilic polymeric component comprising reactive groups.
2 . The hemostatic composition according to claim 1 , wherein the biocompatible polymer and the hydrophilic polymeric component are present in paste form.
3 . The hemostatic composition according to claim 1 , wherein said biocompatible polymer suitable for use in hemostasis contains a member selected from the group consisting of a protein, a polysaccharide, a biologic polymer, a non-biologic polymer, and derivatives and combinations thereof.
4 . The hemostatic composition according to claim 1 , wherein the hydrophilic polymer component is a polyalkylene oxide polymer.
5 . The hemostatic composition according to claim 1 , wherein said hydrophilic polymeric component with reactive groups is a polyethylene glycol (PEG).
6 . The hemostatic composition according to claim 1 , further comprising a binder, wherein the binder contains or is a substance selected from the group consisting of glycerol, a derivative of glycerol, DMSO, ethanol, a polyethyleneglycol, a Poloxamer, and combinations thereof.
7 . The hemostatic composition according to claim 1 , further comprising a binder, wherein the binder has a water content (% v/v) below 5%.
8 . A method of treating a patient, comprising administering to the patient a hemostatic composition according to claim 1 for the treatment of an injury selected from the group consisting of a wound, a hemorrhage, a damaged tissue, a bleeding tissue, qne a bone defect.
9 . A kit for the treatment of an injury selected from the group consisting of a wound, a hemorrhage, a damaged tissue, and a bleeding tissue, comprising:
a) a hemostatic composition according to claim 1 ; and
b) instructions for use
10 . A method for producing a hemostatic composition according to claim 1 comprising the step of mixing a biocompatible polymer suitable for use in hemostasis and one hydrophilic polymeric component comprising reactive groups with a binder wherein the reactivity of the polymeric component is retained.
11 . The hemostatic composition according to claim 2 , wherein the biocompatible polymer and the hydrophilic polymeric component are present with a binder wherein the reactivity of the polymeric component is retained.
12 . The hemostatic composition according to claim 2 , wherein the polyalkylene oxide polymer is a PEG comprising polymer.
13 . The hemostatic composition according to claim 2 , wherein the polyalkylene oxide polymer is a multi-electrophilic polyalkylene oxide polymer.
14 . The hemostatic composition according to claim 2 , wherein the polyalkylene oxide polymer is a multi-electrophilic PEG.
15 . The hemostatic composition according to claim 2 , wherein the polyalkylene oxide polymer is pentaerythritolpoly(ethyleneglycol)ether tetrasuccinimidyl glutarate.
16 . The hemostatic composition according to claim 5 , wherein the hydrophilic polymeric component with reactive groups is a polyethylene glycol (PEG) comprising two or more reactive groups selected from succinimidylesters (—CON(COCH 2 ) 2 ), aldehydes (—CHO) and isocyanates (—N═C═O).
17 . The hemostatic composition according to claim 7 , wherein the binder has a water content (% v/v) below 2%.
18 . The hemostatic composition according to claim 7 , wherein the binder has a water content (% v/v) below 1%.
19 . The method according to claim 10 , wherein the mixing step comprises blending.